Aryan Hoda, Movassaghi Shabnam, Ghasemi Amir, Darabi Roksana
Department of Internal Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Anatomy Department, Islamic Azad University, Tehran Medical Sciences, Tehran, Iran.
Galen Med J. 2020 Oct 3;9:e1557. doi: 10.31661/gmj.v9i0.1557. eCollection 2020.
Lamotrigine is one of the newest antiepileptic drugs that is used as one of the most common treatments in pregnancy. Since the investigation of the teratogenic effects of lamotrigine is very limited and there is no report of its teratogenic effects on fetal gonads, we aimed to investigate the teratogenic effects of lamotrigine on embryonic gonads.
This study was performed on nine female Wistar female rats (8 weeks, weighing 180-200 mg). At first, the animals were inspected regularly by the preparation of vaginal smear and in the estrus phase in separate cages of mating, and after observing the vaginal plaque, were randomly divided into three groups (n=3). Control group did not receive any treatment. In the lamotrigine group (20mg/kg), and the vehicle group (same volume of normal saline) were injected intraperitoneally from days 8 to 13 of pregnancy. On day 20, animals were anesthetized by sodium pentobarbital (40 mg/kg), and embryos were extracted through laparotomy. First, fetuses were weighed, and their height (crown-rump length) was measured. Then the gonads of the fetuses were removed and, stained with H & E, and examined by optical microscope.
Our results showed that in the lamotrigine group, the number of seminiferous tubules and Sertoli cells in the male embryos and the number of oocytes in the female embryos decreased significantly compared to the control and vehicle groups (P≤0.05).
The results of this study showed that treatment with 20 mg/kg lamotrigine in mothers during pregnancy could cause damage to fetal gonads.
拉莫三嗪是最新的抗癫痫药物之一，是孕期最常用的治疗药物之一。由于对拉莫三嗪致畸作用的研究非常有限，且尚无其对胎儿性腺致畸作用的报道，我们旨在研究拉莫三嗪对胚胎性腺的致畸作用。
本研究对9只雌性Wistar大鼠（8周龄，体重180 - 200毫克）进行。首先，通过制备阴道涂片定期检查动物，并在发情期将其置于单独的交配笼中，观察到阴道斑后，将其随机分为三组（n = 3）。对照组不接受任何治疗。拉莫三嗪组（20毫克/千克）和赋形剂组（相同体积的生理盐水）在妊娠第8天至13天腹腔注射。在第20天，用戊巴比妥钠（40毫克/千克）麻醉动物，通过剖腹术取出胚胎。首先，称取胎儿体重，测量其身高（顶臀长度）。然后取出胎儿的性腺，用苏木精和伊红染色，并用光学显微镜检查。
我们的结果显示，与对照组和赋形剂组相比，拉莫三嗪组雄性胚胎的生精小管和支持细胞数量以及雌性胚胎的卵母细胞数量显著减少（P≤0.05）。
本研究结果表明，孕期母亲使用20毫克/千克拉莫三嗪治疗可能会对胎儿性腺造成损害。
